Clinical trial
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
NCT00014352 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00014352 |
|---|---|
| Title | Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer |
| Official title | Phase II Trial Of Sequential Estramustine/Paclitaxel Followed By Doxorubicin/Ketoconazole In Patients With Androgen-Independent Prostate Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Thromboembolism |
| Intervention type | Drug |
| Interventions | docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, ketoconazole, warfarin |
| Start date | Sep 1, 2000 |
| Primary completion | Mar 1, 2003 |
| First posted | Nov 13, 2003 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: